HIV-1 inhibitor-6 

HIV-1 inhibitor-6 (3-Pyridinecarboxamide, 1,4-dihydro-1-methyl-N-(5-nitro-1,2-benzisothiazol-3-yl)-4-oxo-) is a potent HIV-1 pre-mRNA selective splicing inhibitor that blocks HIV replication.

HIV-1inhibitor-62 (Compound 6) is an HIV-1 inhibitor useful for antiviral research.

HIV-1inhibitor-63 (compound S17) is a potent inhibitor of HIV-1. It effectively suppresses the formation of the integrase-Ku70 complex with an IC50 value of 12 µM. Additionally, HIV-1inhibitor-63 impedes the post-integration DNA repair of HIV-1.

HIV-1inhibitor-65 (compound 3c) is an inhibitor of HIV-1 with an EC50 of 2.9 nM and serves as an activator of protein kinase C (PKC). It effectively hinders syncytium formation with an EC50 of 7.0 nM, and prevents HIV-1 entry as well as the action of HIV-1 reverse transcriptase.

HIV-1inhibitor-66 is an orally active non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits inhibitory activity against wild-type HIV-1 reverse transcriptase (HIV-1 reverse transcriptase) with an IC50 of 40 nM.

HIV-1inhibitor-68 (compound 26) is a derivative that activates protein kinase C (PKC) and exhibits latency-reversing activity in HIV-1. It holds potential for eradicating cells latently infected with HIV-1.

HIV-1 Inhibitor-61 (2c) serves as a potent inhibitor of HIV-1 reverse transcriptase, exhibiting an EC50 value of 0.07 nM in NL4-3 wt MT-4 cells [1].

HIV-1 inhibitor-64 (Compound 7c) is an effective wild-type HIV-1 suppressant, also capable of inhibiting HIV-1 mutants E138K/Q148K and G140S/Q148R with EC50 values of 62.5 nM and 11.3 nM, respectively. This compound demonstrates antiviral activity and is applicable in AIDS research [1].

AzddMeC (Az-Dcme) is a nucleoside analog with antiviral activity and is an orally active and selective inhibitor of HIV-1 reverse transcriptase and HIV-1 replication.AzddMeC has an EC50 value of 9 nM against HIV-1-infected human PBM cells and 6 nM against HIV-1-infected human macrophages.

Dolutegravir intermediate-1 (1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid) is a new synthetic Dolutegravir intermediate. Dolutegravir is an integrase inhibitor developed for the treatment of human immunodeficiency virus (HIV)-1 infection.

PF-3450074 (PF-74) acts at an early stage of HIV-1 infection inhibits viral replication by directly competing with the binding of CPSF6 (nuclear host factors cleavage and polyadenylation specific factor 6) and NUP153 (nucleoporin 153), and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle. PF-3450074 is a specifical inhibitor of HIV-1 capsid protein (CA) and shows a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM).

HIV-1 integrase inhibitor 2 is used for the treatment of human immunodeficiency virus (HIV) infection.

RN-18 is an inhibitor of HIV-1 viral infectivity factor (IC50: 6 μM in nonpermissive H9 cells).

Rottlerin (NSC-56346) is a natural product purified from Mallotus Philippinensis and is a specific PKC inhibitor (IC50: PKCδ of 3-6 μM, PKCα,β,γ of 30-42 μM, PKCε,η,ζ of 80-100 μM). Rottlerin causes apoptosis via caspase 3 activation.

NNRT-IN-6 (Compound 13a) is a non-nucleoside reverse transcriptase inhibitor (NNRT) used to inhibit HIV-1 reverse transcriptase (HIV-1RT), with an IC50 of 0.41 μM. It effectively suppresses both wild-type HIV-1 and mutants L100I, K103N, Y181C, Y188L, E138K, F227L/V106A, and RES056, with an EC50 range of 6.2-250 nM.

NNRT-IN-4 (Compound 10p) is an inhibitor of non-nucleoside reverse transcriptase (NNRT) with an IC50 of 0.713 µM for HIV-1RT. It exhibits antiviral activity against both wild-type and mutant strains of HIV-1, with an EC50 ranging from 6 to 63 nM. NNRT-IN-4 shows weak inhibitory activity on hERG (IC50=25.9 µM) and CYP enzymes (IC50>50 µM). In mice, NNRT-IN-4 demonstrates good tolerance and safety at 2 g/kg.

ATPase-IN-6 is an inhibitor of H+/K+-ATPase (ATPase) and a derivative of imidazopyridine. It exhibits significant antiviral activity against various viruses, such as HIV-1 and SARS-CoV-2. ATPase-IN-6 is applicable in antiviral infection research.

1. Isosinensetin (6-Demethoxynobiletin) shows antioxidant and HIV-1 protease inhibiting activities.

HIV-1 inhibitor-15 (compound 9d) is a potent, broad-spectrum inhibitor targeting HIV-1, with EC50 values of 1.7 nM against HIV-1 WT, 4 nM against L100I, 2 nM against K103N, 6 nM against Y181C, and 9 nM against E138K. It exhibits high efficacy, favorable solubility, safety profiles, and oral bioavailability [1].

DENV-IN-6 is a potent inhibitor of DENV (I-IV), demonstrating EC50 values of 17.5, 13.20, 6.8, and 11.41 μM for the inhibition of DENV (I-IV) replication, respectively. Additionally, it exhibits anti-HIV-1 IIIB activity, with an EC50 of 0.0181 µM and a CC50 of 64.92 µM [1].

HIV-1 protease-IN-6 (compound 17d) is a potent HIV-1 protease inhibitor with an IC50 of 21 pM and a Ki of 4.7 pM, demonstrating significant antiviral activity against DRV (darunavir) resistant mutants, surpassing its inhibition efficacy against wild-type viruses.

F1, an anti-inflammatory peptide, incorporates the HIV-1 Tat protein transduction domain linked with a 15-amino acid sequence from residues 46-60 of the inhibitor of NF-κB kinase-interacting peptide (IKIP). It effectively blocks LPS-induced phosphorylation of IκB kinase α (IKKα) and IKKβ, along with the nuclear translocation of NF-κB (p65) in mouse peritoneal macrophages at 5 µM concentration. F1, administered at 5 mg/kg in vivo, significantly reduces IL-6, TNF-α, and IL-1β serum levels and enhances survival in a mouse sepsis model induced by LPS.

Stavudine-α,α,α,6-d4 is a deuterated compound of Stavudine. Stavudine has a CAS number of 3056-17-5. Stavudine, a nucleoside reverse transcriptase inhibitor analog of thymidine, has activity against HIV.